Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
where its EDG-7500 showed benefit as a potential treatment for obstructive hypertrophic cardiomyopathy (HCM). The data comprise results from a Phase I trial in healthy subjects and the single-dose arm of the Phase II CIRRUS-HCM trial. An oral, selective modulator, EDG-7500 is designed to address cardiac relaxation issues associated with HCM. In the placebo-controlled Phase I single ascending dose (SAD) trial, healthy subjects received single doses of EDG-7500, ranging from 5mg to 300mg. The multiple ascending dose (MAD) portion saw subjects receive 25 to 100mg once daily for 14 days. In the trial, EDG-7500 was found to be well-tolerated without any significant changes in vital signs, clinical chemistry, haematology, or electrocardiograms. No meaningful changes in left ventricular ejection fraction (LVEF) were reported for all SAD and MAD subjects across a broad range of EDG-7500 exposures. In Part A of the CIRRUS-HCM trial, patients with obstructive HCM received a single
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Truist Financial Co. from $25.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Why Edgewise Therapeutics Stock Is Up 50% on Thursday [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire
- Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time [YahoYaho
- Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern TimeBusiness Wire
EWTX
Earnings
- 8/8/24 - Beat
EWTX
Sec Filings
- 9/24/24 - Form 4
- 9/24/24 - Form 4
- 9/24/24 - Form 4
- EWTX's page on the SEC website